Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
-

-

-
-
-
?0.80
 
WKN: A2DQQ2 / Symbol: NMRD / Name: Nemaura Medical / Stock / Healthcare Equipment & Supplies / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Nemaura Medical Inc Stock

With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Nemaura Medical Inc stock is not clear.

Pros and Cons of Nemaura Medical Inc in the next few years

Pros
?
G***** c******* t* c**********
?
S********** s********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Nemaura Medical Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Nemaura Medical Inc - - - - - - -
Orasure Tech -2.000% -7.059% -7.961% -13.818% -36.376% -37.500% -38.847%
scPharmaceuticals 9.420% -8.000% -9.211% -61.308% -28.000% -10.000% -
SI-BONE Inc 2.240% -4.196% -1.439% -38.288% -27.895% -45.200% -

Comments

Prediction Buy
Perf. (%) -
Target price 5.510
Change
Ends at 31.03.24

Nemaura Medical Inc. (NASDAQ: NMRD) had its "buy" rating re-affirmed by analysts at EF Hutton Acquisition Co. I. They now have a $6.00 price target on the stock.
Ratings data for NMRD provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -
Target price 5.641
Change
Ends at 28.02.24

Nemaura Medical Inc. (NASDAQ: NMRD) had its "buy" rating re-affirmed by analysts at EF Hutton Acquisition Co. I. They now have a $6.00 price target on the stock.
Ratings data for NMRD provided by MarketBeat
Show more